ATLANTA, United States (AFP) — The anti-cholesterol drug Crestor has been found to reverse plaque buildup in the arteries of the heart, according to a study released.
Unlike other anti-cholesterol …
IN THE WAKE OF new safety issues, AstraZeneca has disclosed plans for a upcoming DTC initiative for Crestor. Noting rapid growth in the U.S. statins market, chief financial officer John Symond told analysts there will be a “disciplined” approach to a marketing mix that carries si…
The Health Research Group charges that Crestor, a recently approved cholesterol-lowering drug, holds more potential harmful side effects than similar medications. But the FDA and manufacturer AstraZeneca PLC assert that the risk-to-benefit equation in Crestor is similar to that of the other drugs.
Related Results
Crestor concernsFDA…
Only a month after getting a government advisory committee’s go-ahead, Crestor (rosuvastatin) has received approval from the Food and Drug Administration (FDA) to be used to fight high cholesterol.
Crestor, a prescription medication, is in a class of drugs known asHMG-CoA reductase inhib…
Robust third quarter performance.
Third quarter sales increased by 3 percent at constant exchange rates (CER). Core EPS increased by 20 percent at CER to $1.32.
Third quarter sales in Emerging Market…
LOS ANGELES — Simvastatin lowered testosterone levels by 41%, normalized gonadotropin levels, and reduced cardiovascular risk factors in a small, randomized, controlled trial, suggesting that statins may be a potential treatment for polycystic ovarian syndrome.
The…
DUBLIN, Ireland–(BUSINESS WIRE)–July 6, 2006–Elan Corporation, plc (NYSE:ELN) today announced that it has entered into a License Agreement with Abbott Pharmaceutical PR Ltd (NYSE:ABT) in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan’s pro…
People involved in the study got their “bad cholesterol” to the lowest levels ever and, as a result, they noticed that blockages in their blood vessels declined. It’s too early to state whether the shrinkage of deposits in arteries will result in fewer heart attacks, but doctors were enthusiastic about the possibility.
“The holy grail has always been to try to reverse the disease,” and this shows how to do it, stated Dr. Steven Nissen, the cardiologist at C…
Par Pharmaceutical Companies, Inc. has announced that it’s partner, Genpharm Inc. of Toronto, Canada, has received final approval from the FDA for its Abbreviated New Drug Application for pravastatin 10 …
…
AstraZeneca, the drug company, said it was halting a 15,000- patient study of its blockbuster cholesterol medicine Crestor, because early findings already proved the drug significantly reduces the risk of heart problems.
The success of the trial raised hopes that Crestor could be expanded for u…
